Neurogene partners with University of Edinburgh on gene therapy research

By The Science Advisory Board staff writers

January 19, 2021 -- Neurogene has entered into a research collaboration with the University of Edinburgh to advance the development of multiple platform approaches to enable next-generation gene therapies.

The collaboration will provide comprehensive research capabilities to Neurogene, enabling the company and university to accelerate platform approaches that improve upon existing gene therapy technologies focused on neurodevelopmental diseases.

Under the terms of the collaboration, Neurogene will provide financial support for the lab of Stuart Cobb, PhD, at the University of Edinburgh, in exchange for the right to license any applicable intellectual property at agreed upon economic terms. Neurogene will be responsible for late stage preclinical and all clinical development of any products generated under the collaboration.

Cobb also serves as the chief scientific officer at Neurogene.

The collaboration has been supported by Edinburgh Innovations, the University of Edinburgh's commercialization service.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.